nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Protein Kinase Inhibitors—Sunitinib—pancreatic cancer	0.324	1	CiPCiCtD
Bosutinib—Vandetanib—Erlotinib—pancreatic cancer	0.125	0.635	CrCrCtD
Bosutinib—Gefitinib—Erlotinib—pancreatic cancer	0.072	0.365	CrCrCtD
Bosutinib—SRC—pancreatic cancer	0.0605	0.598	CbGaD
Bosutinib—EGFR—pancreatic cancer	0.0407	0.402	CbGaD
Bosutinib—ULK3—Erlotinib—pancreatic cancer	0.00795	0.0299	CbGbCtD
Bosutinib—TNIK—Sunitinib—pancreatic cancer	0.00724	0.0273	CbGbCtD
Bosutinib—PHKG1—Sunitinib—pancreatic cancer	0.00724	0.0273	CbGbCtD
Bosutinib—STK33—Sunitinib—pancreatic cancer	0.00724	0.0273	CbGbCtD
Bosutinib—STK24—Sunitinib—pancreatic cancer	0.00724	0.0273	CbGbCtD
Bosutinib—CLK1—Sunitinib—pancreatic cancer	0.00724	0.0273	CbGbCtD
Bosutinib—CSNK1A1—Sunitinib—pancreatic cancer	0.00724	0.0273	CbGbCtD
Bosutinib—MAP4K4—Sunitinib—pancreatic cancer	0.00724	0.0273	CbGbCtD
Bosutinib—SLK—Erlotinib—pancreatic cancer	0.00528	0.0199	CbGbCtD
Bosutinib—CAMK2G—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—ROCK1—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—STK4—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—LOC400927-CSNK1E—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—TBK1—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—LRRK2—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—RPS6KB1—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—MAP2K2—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—ULK3—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—CHEK2—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—MERTK—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—MAP2K1—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—MAST1—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—MAP3K12—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—CSNK1E—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—MAP4K2—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—STK3—Sunitinib—pancreatic cancer	0.00524	0.0197	CbGbCtD
Bosutinib—ALK—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—TYRO3—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—MAP4K1—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—MAP3K7—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—AXL—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—IRAK4—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—BMP2K—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—NUAK2—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—FYN—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—PTK2B—Sunitinib—pancreatic cancer	0.00416	0.0157	CbGbCtD
Bosutinib—HIPK4—Erlotinib—pancreatic cancer	0.00404	0.0152	CbGbCtD
Bosutinib—EGFR—Erlotinib—pancreatic cancer	0.00363	0.0137	CbGbCtD
Bosutinib—ABL2—Erlotinib—pancreatic cancer	0.00363	0.0137	CbGbCtD
Bosutinib—STK10—Erlotinib—pancreatic cancer	0.00363	0.0137	CbGbCtD
Bosutinib—TAOK3—Sunitinib—pancreatic cancer	0.00348	0.0131	CbGbCtD
Bosutinib—YES1—Sunitinib—pancreatic cancer	0.00348	0.0131	CbGbCtD
Bosutinib—MAP3K3—Sunitinib—pancreatic cancer	0.00348	0.0131	CbGbCtD
Bosutinib—SLK—Sunitinib—pancreatic cancer	0.00348	0.0131	CbGbCtD
Bosutinib—MAP4K5—Sunitinib—pancreatic cancer	0.00348	0.0131	CbGbCtD
Bosutinib—MAP2K5—Erlotinib—pancreatic cancer	0.0033	0.0124	CbGbCtD
Bosutinib—MAP3K19—Erlotinib—pancreatic cancer	0.00303	0.0114	CbGbCtD
Bosutinib—FGR—Sunitinib—pancreatic cancer	0.00301	0.0113	CbGbCtD
Bosutinib—IRAK1—Sunitinib—pancreatic cancer	0.00301	0.0113	CbGbCtD
Bosutinib—MAP3K2—Sunitinib—pancreatic cancer	0.00301	0.0113	CbGbCtD
Bosutinib—BLK—Sunitinib—pancreatic cancer	0.00266	0.01	CbGbCtD
Bosutinib—HIPK4—Sunitinib—pancreatic cancer	0.00266	0.01	CbGbCtD
Bosutinib—ABL1—Erlotinib—pancreatic cancer	0.00262	0.00987	CbGbCtD
Bosutinib—EGFR—Docetaxel—pancreatic cancer	0.0024	0.00904	CbGbCtD
Bosutinib—CSF1R—Sunitinib—pancreatic cancer	0.00239	0.009	CbGbCtD
Bosutinib—STK10—Sunitinib—pancreatic cancer	0.00239	0.009	CbGbCtD
Bosutinib—PDGFRB—Sunitinib—pancreatic cancer	0.00217	0.00819	CbGbCtD
Bosutinib—MAP2K5—Sunitinib—pancreatic cancer	0.00217	0.00819	CbGbCtD
Bosutinib—MAP3K19—Sunitinib—pancreatic cancer	0.002	0.00753	CbGbCtD
Bosutinib—SRMS—gall bladder—pancreatic cancer	0.000564	0.0304	CbGeAlD
Bosutinib—STK26—gall bladder—pancreatic cancer	0.000532	0.0287	CbGeAlD
Bosutinib—CLK3—islet of Langerhans—pancreatic cancer	0.000386	0.0209	CbGeAlD
Bosutinib—VRK2—islet of Langerhans—pancreatic cancer	0.000362	0.0195	CbGeAlD
Bosutinib—WEE1—islet of Langerhans—pancreatic cancer	0.000334	0.018	CbGeAlD
Bosutinib—PLK2—islet of Langerhans—pancreatic cancer	0.00031	0.0167	CbGeAlD
Bosutinib—CLK3—pancreas—pancreatic cancer	0.000272	0.0147	CbGeAlD
Bosutinib—Vandetanib—SRC—pancreatic cancer	0.000269	0.247	CrCbGaD
Bosutinib—VRK2—pancreas—pancreatic cancer	0.000255	0.0137	CbGeAlD
Bosutinib—ABCB1—Tamoxifen—pancreatic cancer	0.000254	0.000956	CbGbCtD
Bosutinib—Vandetanib—KDR—pancreatic cancer	0.000253	0.232	CrCbGaD
Bosutinib—STK26—pancreas—pancreatic cancer	0.000245	0.0132	CbGeAlD
Bosutinib—STK33—digestive system—pancreatic cancer	0.000244	0.0132	CbGeAlD
Bosutinib—MAP4K4—islet of Langerhans—pancreatic cancer	0.000242	0.013	CbGeAlD
Bosutinib—NUAK2—islet of Langerhans—pancreatic cancer	0.00024	0.0129	CbGeAlD
Bosutinib—BCR—islet of Langerhans—pancreatic cancer	0.00024	0.0129	CbGeAlD
Bosutinib—WEE1—Paclitaxel—Docetaxel—pancreatic cancer	0.00024	0.229	CbGdCrCtD
Bosutinib—WEE1—pancreas—pancreatic cancer	0.000235	0.0127	CbGeAlD
Bosutinib—STK35—islet of Langerhans—pancreatic cancer	0.000233	0.0126	CbGeAlD
Bosutinib—CLK3—digestive system—pancreatic cancer	0.000232	0.0125	CbGeAlD
Bosutinib—CSK—islet of Langerhans—pancreatic cancer	0.000232	0.0125	CbGeAlD
Bosutinib—CSNK1A1—islet of Langerhans—pancreatic cancer	0.00023	0.0124	CbGeAlD
Bosutinib—CLK1—islet of Langerhans—pancreatic cancer	0.000229	0.0123	CbGeAlD
Bosutinib—EPHB2—digestive system—pancreatic cancer	0.000227	0.0122	CbGeAlD
Bosutinib—STK25—pancreas—pancreatic cancer	0.000224	0.0121	CbGeAlD
Bosutinib—SRMS—digestive system—pancreatic cancer	0.000222	0.012	CbGeAlD
Bosutinib—ABCB1—Gemcitabine—pancreatic cancer	0.000219	0.000824	CbGbCtD
Bosutinib—PLK2—pancreas—pancreatic cancer	0.000218	0.0118	CbGeAlD
Bosutinib—ABCB1—Erlotinib—pancreatic cancer	0.000216	0.000813	CbGbCtD
Bosutinib—Vandetanib—VEGFA—pancreatic cancer	0.000215	0.197	CrCbGaD
Bosutinib—CSNK1E—islet of Langerhans—pancreatic cancer	0.000213	0.0115	CbGeAlD
Bosutinib—SYK—digestive system—pancreatic cancer	0.000213	0.0115	CbGeAlD
Bosutinib—CDK2—digestive system—pancreatic cancer	0.000211	0.0114	CbGeAlD
Bosutinib—SIK1—islet of Langerhans—pancreatic cancer	0.00021	0.0113	CbGeAlD
Bosutinib—IRAK4—islet of Langerhans—pancreatic cancer	0.00021	0.0113	CbGeAlD
Bosutinib—STK26—digestive system—pancreatic cancer	0.000209	0.0113	CbGeAlD
Bosutinib—CAMK1D—pancreas—pancreatic cancer	0.000206	0.0111	CbGeAlD
Bosutinib—MAP2K2—islet of Langerhans—pancreatic cancer	0.000205	0.0111	CbGeAlD
Bosutinib—WEE1—digestive system—pancreatic cancer	0.0002	0.0108	CbGeAlD
Bosutinib—DMPK—digestive system—pancreatic cancer	0.0002	0.0108	CbGeAlD
Bosutinib—PTK2—islet of Langerhans—pancreatic cancer	0.0002	0.0108	CbGeAlD
Bosutinib—TBK1—islet of Langerhans—pancreatic cancer	0.0002	0.0108	CbGeAlD
Bosutinib—IRAK1—islet of Langerhans—pancreatic cancer	0.000196	0.0106	CbGeAlD
Bosutinib—CDK2—Paclitaxel—Docetaxel—pancreatic cancer	0.000195	0.186	CbGdCrCtD
Bosutinib—ABCB1—Irinotecan—pancreatic cancer	0.000195	0.000734	CbGbCtD
Bosutinib—STK25—digestive system—pancreatic cancer	0.000191	0.0103	CbGeAlD
Bosutinib—PDGFRB—gall bladder—pancreatic cancer	0.000188	0.0101	CbGeAlD
Bosutinib—PLK2—digestive system—pancreatic cancer	0.000186	0.01	CbGeAlD
Bosutinib—SLK—islet of Langerhans—pancreatic cancer	0.000183	0.00988	CbGeAlD
Bosutinib—EPHB4—islet of Langerhans—pancreatic cancer	0.000182	0.00981	CbGeAlD
Bosutinib—Vandetanib—EGFR—pancreatic cancer	0.000181	0.166	CrCbGaD
Bosutinib—EPHA2—islet of Langerhans—pancreatic cancer	0.000178	0.00962	CbGeAlD
Bosutinib—STK4—digestive system—pancreatic cancer	0.000178	0.0096	CbGeAlD
Bosutinib—MAP4K5—islet of Langerhans—pancreatic cancer	0.000174	0.00939	CbGeAlD
Bosutinib—Gefitinib—EGFR—pancreatic cancer	0.000172	0.158	CrCbGaD
Bosutinib—MAP4K4—pancreas—pancreatic cancer	0.00017	0.00916	CbGeAlD
Bosutinib—NUAK2—pancreas—pancreatic cancer	0.000169	0.0091	CbGeAlD
Bosutinib—EPHA5—digestive system—pancreatic cancer	0.000168	0.00907	CbGeAlD
Bosutinib—ALK—digestive system—pancreatic cancer	0.000168	0.00907	CbGeAlD
Bosutinib—STK35—pancreas—pancreatic cancer	0.000164	0.00885	CbGeAlD
Bosutinib—CSK—pancreas—pancreatic cancer	0.000163	0.00879	CbGeAlD
Bosutinib—CSNK1A1—pancreas—pancreatic cancer	0.000162	0.00874	CbGeAlD
Bosutinib—CLK1—pancreas—pancreatic cancer	0.000161	0.00868	CbGeAlD
Bosutinib—YES1—islet of Langerhans—pancreatic cancer	0.000161	0.00867	CbGeAlD
Bosutinib—TAOK3—islet of Langerhans—pancreatic cancer	0.000159	0.00856	CbGeAlD
Bosutinib—CAMK2G—pancreas—pancreatic cancer	0.000158	0.00852	CbGeAlD
Bosutinib—ROCK1—digestive system—pancreatic cancer	0.000155	0.00837	CbGeAlD
Bosutinib—SRC—islet of Langerhans—pancreatic cancer	0.000155	0.00834	CbGeAlD
Bosutinib—CYP3A4—Tamoxifen—pancreatic cancer	0.000152	0.000573	CbGbCtD
Bosutinib—BMPR2—digestive system—pancreatic cancer	0.000151	0.00813	CbGeAlD
Bosutinib—CSNK1E—pancreas—pancreatic cancer	0.00015	0.0081	CbGeAlD
Bosutinib—EPHB3—digestive system—pancreatic cancer	0.00015	0.00807	CbGeAlD
Bosutinib—SIK1—pancreas—pancreatic cancer	0.000148	0.00797	CbGeAlD
Bosutinib—MAP4K4—digestive system—pancreatic cancer	0.000145	0.00783	CbGeAlD
Bosutinib—ERBB3—pancreas—pancreatic cancer	0.000145	0.00781	CbGeAlD
Bosutinib—MAP2K2—pancreas—pancreatic cancer	0.000144	0.00779	CbGeAlD
Bosutinib—ABCB1—Docetaxel—pancreatic cancer	0.000143	0.000538	CbGbCtD
Bosutinib—ABCB1—Sunitinib—pancreatic cancer	0.000142	0.000536	CbGbCtD
Bosutinib—PTK2—pancreas—pancreatic cancer	0.00014	0.00758	CbGeAlD
Bosutinib—TBK1—pancreas—pancreatic cancer	0.00014	0.00758	CbGeAlD
Bosutinib—MAP2K1—digestive system—pancreatic cancer	0.00014	0.00756	CbGeAlD
Bosutinib—CSK—digestive system—pancreatic cancer	0.000139	0.00751	CbGeAlD
Bosutinib—CSNK1A1—digestive system—pancreatic cancer	0.000138	0.00746	CbGeAlD
Bosutinib—IRAK1—pancreas—pancreatic cancer	0.000138	0.00743	CbGeAlD
Bosutinib—HCK—digestive system—pancreatic cancer	0.000137	0.00741	CbGeAlD
Bosutinib—CLK1—digestive system—pancreatic cancer	0.000137	0.00741	CbGeAlD
Bosutinib—RPS6KB1—pancreas—pancreatic cancer	0.000135	0.00729	CbGeAlD
Bosutinib—CAMK2G—digestive system—pancreatic cancer	0.000135	0.00728	CbGeAlD
Bosutinib—PTK2B—digestive system—pancreatic cancer	0.00013	0.00703	CbGeAlD
Bosutinib—CYP3A4—Erlotinib—pancreatic cancer	0.000129	0.000487	CbGbCtD
Bosutinib—SLK—pancreas—pancreatic cancer	0.000129	0.00695	CbGeAlD
Bosutinib—CSNK1E—digestive system—pancreatic cancer	0.000128	0.00691	CbGeAlD
Bosutinib—EPHB4—pancreas—pancreatic cancer	0.000128	0.0069	CbGeAlD
Bosutinib—EPHA2—pancreas—pancreatic cancer	0.000125	0.00676	CbGeAlD
Bosutinib—ERBB3—digestive system—pancreatic cancer	0.000124	0.00667	CbGeAlD
Bosutinib—ULK3—digestive system—pancreatic cancer	0.000123	0.00666	CbGeAlD
Bosutinib—MAP2K2—digestive system—pancreatic cancer	0.000123	0.00666	CbGeAlD
Bosutinib—PDGFRB—islet of Langerhans—pancreatic cancer	0.000123	0.00664	CbGeAlD
Bosutinib—MAP4K5—pancreas—pancreatic cancer	0.000122	0.0066	CbGeAlD
Bosutinib—PTK2—digestive system—pancreatic cancer	0.00012	0.00647	CbGeAlD
Bosutinib—TBK1—digestive system—pancreatic cancer	0.00012	0.00647	CbGeAlD
Bosutinib—CYP3A4—Irinotecan—pancreatic cancer	0.000117	0.00044	CbGbCtD
Bosutinib—RPS6KB1—digestive system—pancreatic cancer	0.000115	0.00623	CbGeAlD
Bosutinib—FGR—digestive system—pancreatic cancer	0.000115	0.00619	CbGeAlD
Bosutinib—YES1—pancreas—pancreatic cancer	0.000113	0.00609	CbGeAlD
Bosutinib—TAOK3—pancreas—pancreatic cancer	0.000112	0.00602	CbGeAlD
Bosutinib—ABL1—islet of Langerhans—pancreatic cancer	0.00011	0.00592	CbGeAlD
Bosutinib—EPHB4—digestive system—pancreatic cancer	0.000109	0.00589	CbGeAlD
Bosutinib—SRC—pancreas—pancreatic cancer	0.000109	0.00586	CbGeAlD
Bosutinib—EPHA2—digestive system—pancreatic cancer	0.000107	0.00578	CbGeAlD
Bosutinib—FYN—digestive system—pancreatic cancer	0.000107	0.00577	CbGeAlD
Bosutinib—ABCB1—Doxorubicin—pancreatic cancer	0.000107	0.000401	CbGbCtD
Bosutinib—YES1—digestive system—pancreatic cancer	9.65e-05	0.00521	CbGeAlD
Bosutinib—STK10—digestive system—pancreatic cancer	9.56e-05	0.00516	CbGeAlD
Bosutinib—TAOK3—digestive system—pancreatic cancer	9.52e-05	0.00514	CbGeAlD
Bosutinib—SRC—digestive system—pancreatic cancer	9.28e-05	0.00501	CbGeAlD
Bosutinib—PDGFRB—pancreas—pancreatic cancer	8.65e-05	0.00467	CbGeAlD
Bosutinib—CYP3A4—Docetaxel—pancreatic cancer	8.56e-05	0.000322	CbGbCtD
Bosutinib—CYP3A4—Sunitinib—pancreatic cancer	8.53e-05	0.000321	CbGbCtD
Bosutinib—CSF1R—digestive system—pancreatic cancer	8.33e-05	0.0045	CbGeAlD
Bosutinib—ABL1—Topotecan—Irinotecan—pancreatic cancer	8.14e-05	0.0777	CbGdCrCtD
Bosutinib—WEE1—Daunorubicin—Epirubicin—pancreatic cancer	8.02e-05	0.0766	CbGdCrCtD
Bosutinib—ABL1—pancreas—pancreatic cancer	7.71e-05	0.00416	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—pancreatic cancer	7.42e-05	0.0709	CbGdCrCtD
Bosutinib—PDGFRB—digestive system—pancreatic cancer	7.39e-05	0.00399	CbGeAlD
Bosutinib—ABL1—digestive system—pancreatic cancer	6.59e-05	0.00355	CbGeAlD
Bosutinib—CYP3A4—Doxorubicin—pancreatic cancer	6.38e-05	0.00024	CbGbCtD
Bosutinib—CAMK2G—Azacitidine—Gemcitabine—pancreatic cancer	6.2e-05	0.0592	CbGdCrCtD
Bosutinib—CHEK2—Paclitaxel—Docetaxel—pancreatic cancer	5.99e-05	0.0572	CbGdCrCtD
Bosutinib—Skin disorder—Gemcitabine—pancreatic cancer	3.48e-05	0.000978	CcSEcCtD
Bosutinib—Nervous system disorder—Fluorouracil—pancreatic cancer	3.46e-05	0.000971	CcSEcCtD
Bosutinib—Thrombocytopenia—Fluorouracil—pancreatic cancer	3.45e-05	0.000969	CcSEcCtD
Bosutinib—Dizziness—Tamoxifen—pancreatic cancer	3.45e-05	0.000969	CcSEcCtD
Bosutinib—Dizziness—Erlotinib—pancreatic cancer	3.41e-05	0.000959	CcSEcCtD
Bosutinib—ABCB1—islet of Langerhans—pancreatic cancer	3.41e-05	0.00184	CbGeAlD
Bosutinib—Renal impairment—Doxorubicin—pancreatic cancer	3.4e-05	0.000953	CcSEcCtD
Bosutinib—Erythema multiforme—Docetaxel—pancreatic cancer	3.39e-05	0.000951	CcSEcCtD
Bosutinib—Face oedema—Epirubicin—pancreatic cancer	3.37e-05	0.000947	CcSEcCtD
Bosutinib—Cardiac disorder—Docetaxel—pancreatic cancer	3.33e-05	0.000934	CcSEcCtD
Bosutinib—Vomiting—Tamoxifen—pancreatic cancer	3.32e-05	0.000932	CcSEcCtD
Bosutinib—Rash—Tamoxifen—pancreatic cancer	3.29e-05	0.000924	CcSEcCtD
Bosutinib—Dermatitis—Tamoxifen—pancreatic cancer	3.29e-05	0.000923	CcSEcCtD
Bosutinib—Vomiting—Erlotinib—pancreatic cancer	3.28e-05	0.000922	CcSEcCtD
Bosutinib—Dyspnoea—Irinotecan—pancreatic cancer	3.28e-05	0.000922	CcSEcCtD
Bosutinib—Blood creatinine increased—Epirubicin—pancreatic cancer	3.27e-05	0.000919	CcSEcCtD
Bosutinib—Headache—Tamoxifen—pancreatic cancer	3.27e-05	0.000918	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	3.27e-05	0.000917	CcSEcCtD
Bosutinib—Rash—Erlotinib—pancreatic cancer	3.26e-05	0.000914	CcSEcCtD
Bosutinib—Dermatitis—Erlotinib—pancreatic cancer	3.25e-05	0.000913	CcSEcCtD
Bosutinib—Dehydration—Epirubicin—pancreatic cancer	3.25e-05	0.000912	CcSEcCtD
Bosutinib—Immune system disorder—Docetaxel—pancreatic cancer	3.24e-05	0.000909	CcSEcCtD
Bosutinib—Headache—Erlotinib—pancreatic cancer	3.24e-05	0.000908	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—pancreatic cancer	3.23e-05	0.000907	CcSEcCtD
Bosutinib—Mediastinal disorder—Docetaxel—pancreatic cancer	3.23e-05	0.000907	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	3.21e-05	0.000902	CcSEcCtD
Bosutinib—Asthenia—Sunitinib—pancreatic cancer	3.21e-05	0.0009	CcSEcCtD
Bosutinib—Decreased appetite—Irinotecan—pancreatic cancer	3.2e-05	0.000899	CcSEcCtD
Bosutinib—Dyspnoea—Gemcitabine—pancreatic cancer	3.2e-05	0.000898	CcSEcCtD
Bosutinib—Abdominal pain upper—Epirubicin—pancreatic cancer	3.19e-05	0.000896	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	3.18e-05	0.000893	CcSEcCtD
Bosutinib—Fatigue—Irinotecan—pancreatic cancer	3.17e-05	0.000891	CcSEcCtD
Bosutinib—Pruritus—Sunitinib—pancreatic cancer	3.16e-05	0.000888	CcSEcCtD
Bosutinib—Pain—Irinotecan—pancreatic cancer	3.15e-05	0.000884	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	3.15e-05	0.000883	CcSEcCtD
Bosutinib—Dyspnoea—Fluorouracil—pancreatic cancer	3.14e-05	0.000883	CcSEcCtD
Bosutinib—Nasopharyngitis—Epirubicin—pancreatic cancer	3.12e-05	0.000877	CcSEcCtD
Bosutinib—Face oedema—Doxorubicin—pancreatic cancer	3.12e-05	0.000876	CcSEcCtD
Bosutinib—Malnutrition—Docetaxel—pancreatic cancer	3.12e-05	0.000876	CcSEcCtD
Bosutinib—Decreased appetite—Gemcitabine—pancreatic cancer	3.12e-05	0.000875	CcSEcCtD
Bosutinib—Nausea—Tamoxifen—pancreatic cancer	3.1e-05	0.00087	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	3.1e-05	0.000869	CcSEcCtD
Bosutinib—Fatigue—Gemcitabine—pancreatic cancer	3.09e-05	0.000868	CcSEcCtD
Bosutinib—Gastritis—Epirubicin—pancreatic cancer	3.09e-05	0.000868	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	3.08e-05	0.000865	CcSEcCtD
Bosutinib—Pain—Gemcitabine—pancreatic cancer	3.07e-05	0.000861	CcSEcCtD
Bosutinib—Nausea—Erlotinib—pancreatic cancer	3.07e-05	0.000861	CcSEcCtD
Bosutinib—Decreased appetite—Fluorouracil—pancreatic cancer	3.07e-05	0.000861	CcSEcCtD
Bosutinib—Diarrhoea—Sunitinib—pancreatic cancer	3.06e-05	0.000859	CcSEcCtD
Bosutinib—Dysgeusia—Docetaxel—pancreatic cancer	3.05e-05	0.000857	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	3.04e-05	0.000855	CcSEcCtD
Bosutinib—Feeling abnormal—Irinotecan—pancreatic cancer	3.03e-05	0.000852	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—pancreatic cancer	3.03e-05	0.00085	CcSEcCtD
Bosutinib—Influenza—Epirubicin—pancreatic cancer	3.02e-05	0.000848	CcSEcCtD
Bosutinib—Back pain—Docetaxel—pancreatic cancer	3.02e-05	0.000847	CcSEcCtD
Bosutinib—Pain—Fluorouracil—pancreatic cancer	3.02e-05	0.000847	CcSEcCtD
Bosutinib—Gastrointestinal pain—Irinotecan—pancreatic cancer	3.01e-05	0.000845	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—pancreatic cancer	3.01e-05	0.000844	CcSEcCtD
Bosutinib—Dizziness—Sunitinib—pancreatic cancer	2.96e-05	0.00083	CcSEcCtD
Bosutinib—Feeling abnormal—Gemcitabine—pancreatic cancer	2.96e-05	0.00083	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—pancreatic cancer	2.95e-05	0.000829	CcSEcCtD
Bosutinib—Body temperature increased—Irinotecan—pancreatic cancer	2.91e-05	0.000817	CcSEcCtD
Bosutinib—Abdominal pain—Irinotecan—pancreatic cancer	2.91e-05	0.000817	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	2.91e-05	0.000817	CcSEcCtD
Bosutinib—Feeling abnormal—Fluorouracil—pancreatic cancer	2.91e-05	0.000816	CcSEcCtD
Bosutinib—Bronchitis—Epirubicin—pancreatic cancer	2.9e-05	0.000815	CcSEcCtD
Bosutinib—CYP3A4—digestive system—pancreatic cancer	2.89e-05	0.00156	CbGeAlD
Bosutinib—Nasopharyngitis—Doxorubicin—pancreatic cancer	2.89e-05	0.000811	CcSEcCtD
Bosutinib—Anaemia—Docetaxel—pancreatic cancer	2.88e-05	0.000809	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—pancreatic cancer	2.87e-05	0.000805	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—pancreatic cancer	2.86e-05	0.000803	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	2.85e-05	0.0008	CcSEcCtD
Bosutinib—Vomiting—Sunitinib—pancreatic cancer	2.84e-05	0.000798	CcSEcCtD
Bosutinib—Body temperature increased—Gemcitabine—pancreatic cancer	2.84e-05	0.000796	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—pancreatic cancer	2.82e-05	0.000793	CcSEcCtD
Bosutinib—Rash—Sunitinib—pancreatic cancer	2.82e-05	0.000791	CcSEcCtD
Bosutinib—Dermatitis—Sunitinib—pancreatic cancer	2.82e-05	0.000791	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Epirubicin—pancreatic cancer	2.81e-05	0.000788	CcSEcCtD
Bosutinib—Urticaria—Fluorouracil—pancreatic cancer	2.8e-05	0.000787	CcSEcCtD
Bosutinib—Headache—Sunitinib—pancreatic cancer	2.8e-05	0.000786	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—pancreatic cancer	2.79e-05	0.000784	CcSEcCtD
Bosutinib—Leukopenia—Docetaxel—pancreatic cancer	2.79e-05	0.000784	CcSEcCtD
Bosutinib—Body temperature increased—Fluorouracil—pancreatic cancer	2.79e-05	0.000783	CcSEcCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—pancreatic cancer	2.74e-05	0.0262	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—pancreatic cancer	2.74e-05	0.0262	CbGdCrCtD
Bosutinib—Cough—Docetaxel—pancreatic cancer	2.72e-05	0.000764	CcSEcCtD
Bosutinib—Pneumonia—Epirubicin—pancreatic cancer	2.71e-05	0.00076	CcSEcCtD
Bosutinib—Infestation NOS—Epirubicin—pancreatic cancer	2.69e-05	0.000756	CcSEcCtD
Bosutinib—Infestation—Epirubicin—pancreatic cancer	2.69e-05	0.000756	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—pancreatic cancer	2.69e-05	0.000754	CcSEcCtD
Bosutinib—Arthralgia—Docetaxel—pancreatic cancer	2.66e-05	0.000745	CcSEcCtD
Bosutinib—Chest pain—Docetaxel—pancreatic cancer	2.66e-05	0.000745	CcSEcCtD
Bosutinib—Myalgia—Docetaxel—pancreatic cancer	2.66e-05	0.000745	CcSEcCtD
Bosutinib—Nausea—Sunitinib—pancreatic cancer	2.66e-05	0.000745	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—pancreatic cancer	2.65e-05	0.000745	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—pancreatic cancer	2.65e-05	0.000743	CcSEcCtD
Bosutinib—Asthenia—Irinotecan—pancreatic cancer	2.64e-05	0.000742	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	2.64e-05	0.00074	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—pancreatic cancer	2.61e-05	0.000733	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	2.6e-05	0.000729	CcSEcCtD
Bosutinib—Asthenia—Gemcitabine—pancreatic cancer	2.57e-05	0.000723	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	2.55e-05	0.000715	CcSEcCtD
Bosutinib—Anaphylactic shock—Docetaxel—pancreatic cancer	2.55e-05	0.000715	CcSEcCtD
Bosutinib—Oedema—Docetaxel—pancreatic cancer	2.55e-05	0.000715	CcSEcCtD
Bosutinib—Pruritus—Gemcitabine—pancreatic cancer	2.54e-05	0.000712	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—pancreatic cancer	2.54e-05	0.0242	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—pancreatic cancer	2.54e-05	0.0242	CbGdCrCtD
Bosutinib—Infection—Docetaxel—pancreatic cancer	2.53e-05	0.00071	CcSEcCtD
Bosutinib—Diarrhoea—Irinotecan—pancreatic cancer	2.52e-05	0.000707	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—pancreatic cancer	2.51e-05	0.000705	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—pancreatic cancer	2.51e-05	0.000703	CcSEcCtD
Bosutinib—Nervous system disorder—Docetaxel—pancreatic cancer	2.5e-05	0.000701	CcSEcCtD
Bosutinib—Pruritus—Fluorouracil—pancreatic cancer	2.5e-05	0.000701	CcSEcCtD
Bosutinib—Thrombocytopenia—Docetaxel—pancreatic cancer	2.49e-05	0.0007	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—pancreatic cancer	2.49e-05	0.000699	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—pancreatic cancer	2.49e-05	0.000699	CcSEcCtD
Bosutinib—Skin disorder—Docetaxel—pancreatic cancer	2.47e-05	0.000694	CcSEcCtD
Bosutinib—Diarrhoea—Gemcitabine—pancreatic cancer	2.45e-05	0.000689	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—pancreatic cancer	2.45e-05	0.000687	CcSEcCtD
Bosutinib—Dizziness—Irinotecan—pancreatic cancer	2.44e-05	0.000684	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—pancreatic cancer	2.42e-05	0.000678	CcSEcCtD
Bosutinib—Diarrhoea—Fluorouracil—pancreatic cancer	2.41e-05	0.000677	CcSEcCtD
Bosutinib—ABCB1—pancreas—pancreatic cancer	2.4e-05	0.00129	CbGeAlD
Bosutinib—Urinary tract disorder—Epirubicin—pancreatic cancer	2.39e-05	0.00067	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—pancreatic cancer	2.38e-05	0.000668	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—pancreatic cancer	2.37e-05	0.000667	CcSEcCtD
Bosutinib—Urethral disorder—Epirubicin—pancreatic cancer	2.37e-05	0.000665	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	2.36e-05	0.000661	CcSEcCtD
Bosutinib—Vomiting—Irinotecan—pancreatic cancer	2.34e-05	0.000657	CcSEcCtD
Bosutinib—Dizziness—Fluorouracil—pancreatic cancer	2.33e-05	0.000655	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—pancreatic cancer	2.32e-05	0.000653	CcSEcCtD
Bosutinib—Rash—Irinotecan—pancreatic cancer	2.32e-05	0.000652	CcSEcCtD
Bosutinib—Dermatitis—Irinotecan—pancreatic cancer	2.32e-05	0.000651	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	2.32e-05	0.000651	CcSEcCtD
Bosutinib—Headache—Irinotecan—pancreatic cancer	2.31e-05	0.000648	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—pancreatic cancer	2.29e-05	0.000641	CcSEcCtD
Bosutinib—Vomiting—Gemcitabine—pancreatic cancer	2.28e-05	0.00064	CcSEcCtD
Bosutinib—Dyspnoea—Docetaxel—pancreatic cancer	2.27e-05	0.000637	CcSEcCtD
Bosutinib—Rash—Gemcitabine—pancreatic cancer	2.26e-05	0.000635	CcSEcCtD
Bosutinib—Dermatitis—Gemcitabine—pancreatic cancer	2.26e-05	0.000634	CcSEcCtD
Bosutinib—Tinnitus—Epirubicin—pancreatic cancer	2.25e-05	0.000633	CcSEcCtD
Bosutinib—Headache—Gemcitabine—pancreatic cancer	2.25e-05	0.000631	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—pancreatic cancer	2.24e-05	0.00063	CcSEcCtD
Bosutinib—Vomiting—Fluorouracil—pancreatic cancer	2.24e-05	0.00063	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—pancreatic cancer	2.24e-05	0.000628	CcSEcCtD
Bosutinib—Rash—Fluorouracil—pancreatic cancer	2.22e-05	0.000624	CcSEcCtD
Bosutinib—Dermatitis—Fluorouracil—pancreatic cancer	2.22e-05	0.000624	CcSEcCtD
Bosutinib—Decreased appetite—Docetaxel—pancreatic cancer	2.21e-05	0.000621	CcSEcCtD
Bosutinib—Headache—Fluorouracil—pancreatic cancer	2.21e-05	0.00062	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—pancreatic cancer	2.21e-05	0.00062	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—pancreatic cancer	2.2e-05	0.000618	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	2.2e-05	0.000617	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	2.2e-05	0.000617	CcSEcCtD
Bosutinib—Fatigue—Docetaxel—pancreatic cancer	2.19e-05	0.000616	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—pancreatic cancer	2.19e-05	0.000615	CcSEcCtD
Bosutinib—Nausea—Irinotecan—pancreatic cancer	2.19e-05	0.000614	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—pancreatic cancer	2.18e-05	0.000613	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—pancreatic cancer	2.18e-05	0.000611	CcSEcCtD
Bosutinib—Pain—Docetaxel—pancreatic cancer	2.18e-05	0.000611	CcSEcCtD
Bosutinib—Nausea—Gemcitabine—pancreatic cancer	2.13e-05	0.000598	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—pancreatic cancer	2.11e-05	0.000594	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—pancreatic cancer	2.1e-05	0.000591	CcSEcCtD
Bosutinib—Feeling abnormal—Docetaxel—pancreatic cancer	2.1e-05	0.000589	CcSEcCtD
Bosutinib—Nausea—Fluorouracil—pancreatic cancer	2.09e-05	0.000588	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—pancreatic cancer	2.08e-05	0.000585	CcSEcCtD
Bosutinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	2.08e-05	0.000584	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—pancreatic cancer	2.08e-05	0.000583	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—pancreatic cancer	2.06e-05	0.000578	CcSEcCtD
Bosutinib—ABCB1—digestive system—pancreatic cancer	2.05e-05	0.00111	CbGeAlD
Bosutinib—Back pain—Epirubicin—pancreatic cancer	2.03e-05	0.000571	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—pancreatic cancer	2.02e-05	0.000567	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	2.02e-05	0.000566	CcSEcCtD
Bosutinib—Body temperature increased—Docetaxel—pancreatic cancer	2.01e-05	0.000565	CcSEcCtD
Bosutinib—Abdominal pain—Docetaxel—pancreatic cancer	2.01e-05	0.000565	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—pancreatic cancer	2.01e-05	0.0192	CbGdCrCtD
Bosutinib—Ill-defined disorder—Epirubicin—pancreatic cancer	1.95e-05	0.000548	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—pancreatic cancer	1.95e-05	0.000546	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—pancreatic cancer	1.94e-05	0.000546	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—pancreatic cancer	1.91e-05	0.0183	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—pancreatic cancer	1.91e-05	0.0183	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—pancreatic cancer	1.91e-05	0.0183	CbGdCrCtD
Bosutinib—Dysgeusia—Doxorubicin—pancreatic cancer	1.91e-05	0.000535	CcSEcCtD
Bosutinib—Malaise—Epirubicin—pancreatic cancer	1.9e-05	0.000533	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—pancreatic cancer	1.88e-05	0.000529	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—pancreatic cancer	1.88e-05	0.000529	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—pancreatic cancer	1.86e-05	0.0177	CbGdCrCtD
Bosutinib—Cough—Epirubicin—pancreatic cancer	1.84e-05	0.000515	CcSEcCtD
Bosutinib—Asthenia—Docetaxel—pancreatic cancer	1.83e-05	0.000513	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—pancreatic cancer	1.81e-05	0.000507	CcSEcCtD
Bosutinib—Pruritus—Docetaxel—pancreatic cancer	1.8e-05	0.000506	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—pancreatic cancer	1.8e-05	0.000505	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—pancreatic cancer	1.79e-05	0.000503	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—pancreatic cancer	1.79e-05	0.000503	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—pancreatic cancer	1.79e-05	0.000503	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	1.78e-05	0.000499	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—pancreatic cancer	1.77e-05	0.0169	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—pancreatic cancer	1.77e-05	0.0169	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—pancreatic cancer	1.77e-05	0.0169	CbGdCrCtD
Bosutinib—Discomfort—Epirubicin—pancreatic cancer	1.77e-05	0.000497	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—pancreatic cancer	1.76e-05	0.000493	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—pancreatic cancer	1.74e-05	0.000489	CcSEcCtD
Bosutinib—Diarrhoea—Docetaxel—pancreatic cancer	1.74e-05	0.000489	CcSEcCtD
Bosutinib—Oedema—Epirubicin—pancreatic cancer	1.72e-05	0.000482	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—pancreatic cancer	1.72e-05	0.000482	CcSEcCtD
Bosutinib—Infection—Epirubicin—pancreatic cancer	1.71e-05	0.000479	CcSEcCtD
Bosutinib—Cough—Doxorubicin—pancreatic cancer	1.7e-05	0.000477	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—pancreatic cancer	1.68e-05	0.000473	CcSEcCtD
Bosutinib—Dizziness—Docetaxel—pancreatic cancer	1.68e-05	0.000473	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—pancreatic cancer	1.68e-05	0.000472	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—pancreatic cancer	1.67e-05	0.000468	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—pancreatic cancer	1.66e-05	0.000465	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—pancreatic cancer	1.66e-05	0.000465	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—pancreatic cancer	1.66e-05	0.000465	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	1.65e-05	0.000462	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—pancreatic cancer	1.64e-05	0.00046	CcSEcCtD
Bosutinib—Vomiting—Docetaxel—pancreatic cancer	1.62e-05	0.000454	CcSEcCtD
Bosutinib—Rash—Docetaxel—pancreatic cancer	1.61e-05	0.000451	CcSEcCtD
Bosutinib—Dermatitis—Docetaxel—pancreatic cancer	1.6e-05	0.00045	CcSEcCtD
Bosutinib—Headache—Docetaxel—pancreatic cancer	1.59e-05	0.000448	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—pancreatic cancer	1.59e-05	0.000446	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—pancreatic cancer	1.59e-05	0.000446	CcSEcCtD
Bosutinib—Infection—Doxorubicin—pancreatic cancer	1.58e-05	0.000443	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	1.56e-05	0.000439	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—pancreatic cancer	1.56e-05	0.000437	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	1.56e-05	0.000437	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—pancreatic cancer	1.54e-05	0.000433	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—pancreatic cancer	1.53e-05	0.00043	CcSEcCtD
Bosutinib—Nausea—Docetaxel—pancreatic cancer	1.51e-05	0.000424	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—pancreatic cancer	1.49e-05	0.000419	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	1.48e-05	0.000416	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—pancreatic cancer	1.48e-05	0.000416	CcSEcCtD
Bosutinib—Pain—Epirubicin—pancreatic cancer	1.47e-05	0.000412	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	1.45e-05	0.000406	CcSEcCtD
Bosutinib—Dyspnoea—Doxorubicin—pancreatic cancer	1.42e-05	0.000398	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—pancreatic cancer	1.41e-05	0.000397	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	1.4e-05	0.000394	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—pancreatic cancer	1.38e-05	0.000388	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.37e-05	0.000385	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—pancreatic cancer	1.37e-05	0.000385	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—pancreatic cancer	1.36e-05	0.000383	CcSEcCtD
Bosutinib—Pain—Doxorubicin—pancreatic cancer	1.36e-05	0.000381	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—pancreatic cancer	1.36e-05	0.000381	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—pancreatic cancer	1.36e-05	0.000381	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—pancreatic cancer	1.31e-05	0.000368	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.3e-05	0.000365	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—pancreatic cancer	1.26e-05	0.000354	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—pancreatic cancer	1.26e-05	0.000353	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—pancreatic cancer	1.26e-05	0.000353	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—pancreatic cancer	1.23e-05	0.000346	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—pancreatic cancer	1.21e-05	0.000341	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—pancreatic cancer	1.17e-05	0.00033	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—pancreatic cancer	1.14e-05	0.00032	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—pancreatic cancer	1.14e-05	0.000319	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—pancreatic cancer	1.12e-05	0.000316	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—pancreatic cancer	1.09e-05	0.000306	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—pancreatic cancer	1.09e-05	0.000305	CcSEcCtD
Bosutinib—Rash—Epirubicin—pancreatic cancer	1.08e-05	0.000304	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—pancreatic cancer	1.08e-05	0.000304	CcSEcCtD
Bosutinib—Headache—Epirubicin—pancreatic cancer	1.08e-05	0.000302	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—pancreatic cancer	1.05e-05	0.000295	CcSEcCtD
Bosutinib—Nausea—Epirubicin—pancreatic cancer	1.02e-05	0.000286	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—pancreatic cancer	1.01e-05	0.000284	CcSEcCtD
Bosutinib—Rash—Doxorubicin—pancreatic cancer	1e-05	0.000281	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—pancreatic cancer	1e-05	0.000281	CcSEcCtD
Bosutinib—Headache—Doxorubicin—pancreatic cancer	9.95e-06	0.000279	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—pancreatic cancer	9.44e-06	0.000265	CcSEcCtD
Bosutinib—SRC—Disease—PTEN—pancreatic cancer	1.94e-07	3.46e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—pancreatic cancer	1.94e-07	3.46e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—pancreatic cancer	1.93e-07	3.46e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—pancreatic cancer	1.93e-07	3.46e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—pancreatic cancer	1.93e-07	3.46e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—pancreatic cancer	1.93e-07	3.45e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—pancreatic cancer	1.93e-07	3.44e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—pancreatic cancer	1.92e-07	3.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PIK3CA—pancreatic cancer	1.92e-07	3.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—pancreatic cancer	1.92e-07	3.43e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CTNNB1—pancreatic cancer	1.92e-07	3.43e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTEN—pancreatic cancer	1.91e-07	3.41e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—pancreatic cancer	1.91e-07	3.41e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—pancreatic cancer	1.91e-07	3.41e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	1.9e-07	3.39e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—pancreatic cancer	1.9e-07	3.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—pancreatic cancer	1.89e-07	3.38e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CTNNB1—pancreatic cancer	1.89e-07	3.38e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—pancreatic cancer	1.89e-07	3.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—pancreatic cancer	1.89e-07	3.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—pancreatic cancer	1.88e-07	3.37e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—pancreatic cancer	1.88e-07	3.36e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—pancreatic cancer	1.88e-07	3.36e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CTNNB1—pancreatic cancer	1.88e-07	3.36e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—STAT3—pancreatic cancer	1.88e-07	3.35e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NRAS—pancreatic cancer	1.87e-07	3.35e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTEN—pancreatic cancer	1.87e-07	3.34e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—pancreatic cancer	1.87e-07	3.34e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—pancreatic cancer	1.86e-07	3.33e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—pancreatic cancer	1.86e-07	3.33e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—pancreatic cancer	1.86e-07	3.32e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—pancreatic cancer	1.86e-07	3.32e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—pancreatic cancer	1.85e-07	3.31e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—pancreatic cancer	1.85e-07	3.31e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—pancreatic cancer	1.85e-07	3.3e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—pancreatic cancer	1.84e-07	3.3e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—pancreatic cancer	1.84e-07	3.29e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTEN—pancreatic cancer	1.84e-07	3.29e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—pancreatic cancer	1.84e-07	3.29e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CB—pancreatic cancer	1.84e-07	3.29e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTEN—pancreatic cancer	1.83e-07	3.27e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—pancreatic cancer	1.83e-07	3.26e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—pancreatic cancer	1.82e-07	3.26e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—pancreatic cancer	1.82e-07	3.25e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—pancreatic cancer	1.82e-07	3.25e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—pancreatic cancer	1.82e-07	3.25e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SRC—pancreatic cancer	1.81e-07	3.24e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—pancreatic cancer	1.81e-07	3.24e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CD—pancreatic cancer	1.8e-07	3.22e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—pancreatic cancer	1.79e-07	3.21e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—pancreatic cancer	1.79e-07	3.19e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—pancreatic cancer	1.78e-07	3.18e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—pancreatic cancer	1.78e-07	3.18e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CB—pancreatic cancer	1.77e-07	3.17e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—pancreatic cancer	1.77e-07	3.17e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SRC—pancreatic cancer	1.77e-07	3.17e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—pancreatic cancer	1.77e-07	3.16e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—pancreatic cancer	1.77e-07	3.16e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—pancreatic cancer	1.77e-07	3.16e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—pancreatic cancer	1.76e-07	3.14e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—pancreatic cancer	1.75e-07	3.13e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—pancreatic cancer	1.74e-07	3.12e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—pancreatic cancer	1.74e-07	3.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—pancreatic cancer	1.74e-07	3.12e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—pancreatic cancer	1.73e-07	3.1e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—pancreatic cancer	1.73e-07	3.1e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SRC—pancreatic cancer	1.73e-07	3.1e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—pancreatic cancer	1.73e-07	3.1e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—pancreatic cancer	1.73e-07	3.09e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—pancreatic cancer	1.72e-07	3.08e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—pancreatic cancer	1.72e-07	3.07e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—pancreatic cancer	1.71e-07	3.07e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—pancreatic cancer	1.71e-07	3.06e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—pancreatic cancer	1.71e-07	3.05e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—pancreatic cancer	1.71e-07	3.05e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—pancreatic cancer	1.71e-07	3.05e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SRC—pancreatic cancer	1.71e-07	3.05e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—pancreatic cancer	1.71e-07	3.05e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—pancreatic cancer	1.7e-07	3.05e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—pancreatic cancer	1.7e-07	3.05e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—pancreatic cancer	1.7e-07	3.05e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—pancreatic cancer	1.7e-07	3.04e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SRC—pancreatic cancer	1.7e-07	3.04e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—pancreatic cancer	1.69e-07	3.03e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—pancreatic cancer	1.69e-07	3.02e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—pancreatic cancer	1.68e-07	3e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—pancreatic cancer	1.68e-07	3e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—pancreatic cancer	1.67e-07	2.99e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—pancreatic cancer	1.67e-07	2.99e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—pancreatic cancer	1.67e-07	2.98e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—pancreatic cancer	1.67e-07	2.98e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—pancreatic cancer	1.66e-07	2.97e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—pancreatic cancer	1.66e-07	2.97e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—pancreatic cancer	1.66e-07	2.97e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—pancreatic cancer	1.65e-07	2.96e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—pancreatic cancer	1.65e-07	2.95e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—pancreatic cancer	1.65e-07	2.94e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—pancreatic cancer	1.65e-07	2.94e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—pancreatic cancer	1.64e-07	2.94e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—pancreatic cancer	1.64e-07	2.93e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—pancreatic cancer	1.64e-07	2.93e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—pancreatic cancer	1.64e-07	2.93e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—pancreatic cancer	1.63e-07	2.92e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—pancreatic cancer	1.63e-07	2.92e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—pancreatic cancer	1.63e-07	2.92e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—pancreatic cancer	1.63e-07	2.92e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—pancreatic cancer	1.63e-07	2.91e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—pancreatic cancer	1.62e-07	2.9e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—pancreatic cancer	1.62e-07	2.9e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—pancreatic cancer	1.61e-07	2.88e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—pancreatic cancer	1.61e-07	2.88e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—pancreatic cancer	1.61e-07	2.88e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOE—pancreatic cancer	1.61e-07	2.87e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—pancreatic cancer	1.61e-07	2.87e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—pancreatic cancer	1.6e-07	2.87e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—pancreatic cancer	1.6e-07	2.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—pancreatic cancer	1.6e-07	2.86e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—pancreatic cancer	1.59e-07	2.84e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—pancreatic cancer	1.59e-07	2.84e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—pancreatic cancer	1.59e-07	2.84e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—pancreatic cancer	1.59e-07	2.84e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—pancreatic cancer	1.58e-07	2.83e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—pancreatic cancer	1.58e-07	2.82e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—pancreatic cancer	1.57e-07	2.81e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—pancreatic cancer	1.57e-07	2.81e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—pancreatic cancer	1.57e-07	2.81e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—pancreatic cancer	1.57e-07	2.81e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CD44—pancreatic cancer	1.57e-07	2.81e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—pancreatic cancer	1.55e-07	2.78e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—pancreatic cancer	1.55e-07	2.77e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—pancreatic cancer	1.55e-07	2.77e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—pancreatic cancer	1.55e-07	2.77e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—pancreatic cancer	1.55e-07	2.77e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—pancreatic cancer	1.55e-07	2.77e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—pancreatic cancer	1.54e-07	2.76e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—pancreatic cancer	1.54e-07	2.76e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—pancreatic cancer	1.53e-07	2.74e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—pancreatic cancer	1.53e-07	2.73e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—pancreatic cancer	1.53e-07	2.73e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—pancreatic cancer	1.53e-07	2.73e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—pancreatic cancer	1.52e-07	2.72e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—pancreatic cancer	1.52e-07	2.72e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—pancreatic cancer	1.52e-07	2.71e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—pancreatic cancer	1.51e-07	2.71e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—pancreatic cancer	1.51e-07	2.7e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—pancreatic cancer	1.51e-07	2.69e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GCG—pancreatic cancer	1.5e-07	2.69e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—pancreatic cancer	1.5e-07	2.69e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—pancreatic cancer	1.5e-07	2.67e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—pancreatic cancer	1.49e-07	2.66e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—pancreatic cancer	1.49e-07	2.66e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—pancreatic cancer	1.48e-07	2.65e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—pancreatic cancer	1.48e-07	2.65e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SRC—pancreatic cancer	1.47e-07	2.64e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—pancreatic cancer	1.47e-07	2.62e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—pancreatic cancer	1.46e-07	2.62e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—pancreatic cancer	1.46e-07	2.61e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.45e-07	2.59e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—pancreatic cancer	1.44e-07	2.58e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—pancreatic cancer	1.44e-07	2.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—pancreatic cancer	1.44e-07	2.57e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—pancreatic cancer	1.43e-07	2.57e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—pancreatic cancer	1.43e-07	2.55e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—pancreatic cancer	1.42e-07	2.54e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SRC—pancreatic cancer	1.42e-07	2.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—pancreatic cancer	1.42e-07	2.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—pancreatic cancer	1.42e-07	2.53e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—STK11—pancreatic cancer	1.41e-07	2.53e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—pancreatic cancer	1.41e-07	2.53e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—pancreatic cancer	1.41e-07	2.51e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—pancreatic cancer	1.4e-07	2.51e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—pancreatic cancer	1.4e-07	2.5e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—pancreatic cancer	1.39e-07	2.49e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—pancreatic cancer	1.38e-07	2.47e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—pancreatic cancer	1.38e-07	2.47e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—pancreatic cancer	1.37e-07	2.45e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—pancreatic cancer	1.37e-07	2.45e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—pancreatic cancer	1.37e-07	2.45e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—pancreatic cancer	1.37e-07	2.44e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—pancreatic cancer	1.37e-07	2.44e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—pancreatic cancer	1.37e-07	2.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—pancreatic cancer	1.36e-07	2.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—pancreatic cancer	1.36e-07	2.43e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—pancreatic cancer	1.35e-07	2.41e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—pancreatic cancer	1.33e-07	2.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—pancreatic cancer	1.32e-07	2.36e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—pancreatic cancer	1.32e-07	2.36e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—pancreatic cancer	1.32e-07	2.36e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—pancreatic cancer	1.31e-07	2.34e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—pancreatic cancer	1.3e-07	2.33e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—pancreatic cancer	1.3e-07	2.32e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—pancreatic cancer	1.29e-07	2.31e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—pancreatic cancer	1.29e-07	2.31e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—pancreatic cancer	1.28e-07	2.28e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—pancreatic cancer	1.28e-07	2.28e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.27e-07	2.28e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—pancreatic cancer	1.27e-07	2.28e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—pancreatic cancer	1.27e-07	2.27e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—pancreatic cancer	1.26e-07	2.26e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—pancreatic cancer	1.26e-07	2.25e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—pancreatic cancer	1.26e-07	2.25e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—pancreatic cancer	1.25e-07	2.23e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—pancreatic cancer	1.25e-07	2.23e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—pancreatic cancer	1.24e-07	2.23e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—pancreatic cancer	1.22e-07	2.19e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—pancreatic cancer	1.22e-07	2.18e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—pancreatic cancer	1.22e-07	2.18e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.22e-07	2.18e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—pancreatic cancer	1.21e-07	2.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—pancreatic cancer	1.21e-07	2.16e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—pancreatic cancer	1.21e-07	2.16e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—pancreatic cancer	1.2e-07	2.15e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—pancreatic cancer	1.19e-07	2.14e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—pancreatic cancer	1.18e-07	2.1e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—pancreatic cancer	1.13e-07	2.02e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—pancreatic cancer	1.13e-07	2.02e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—pancreatic cancer	1.12e-07	2.01e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—pancreatic cancer	1.12e-07	2.01e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—pancreatic cancer	1.12e-07	2e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.11e-07	1.99e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—pancreatic cancer	1.1e-07	1.97e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.1e-07	1.97e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—pancreatic cancer	1.1e-07	1.97e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—pancreatic cancer	1.08e-07	1.94e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—pancreatic cancer	1.08e-07	1.93e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—pancreatic cancer	1.08e-07	1.93e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—pancreatic cancer	1.06e-07	1.9e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—pancreatic cancer	1.05e-07	1.89e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—pancreatic cancer	1.05e-07	1.87e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—pancreatic cancer	1.04e-07	1.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—pancreatic cancer	1.04e-07	1.86e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—pancreatic cancer	1e-07	1.79e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOE—pancreatic cancer	9.89e-08	1.77e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—pancreatic cancer	9.59e-08	1.72e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—pancreatic cancer	9.57e-08	1.71e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—pancreatic cancer	9.25e-08	1.66e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—pancreatic cancer	9.16e-08	1.64e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	8.93e-08	1.6e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—pancreatic cancer	8.85e-08	1.58e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—pancreatic cancer	8.83e-08	1.58e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	8.62e-08	1.54e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	7.85e-08	1.4e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—pancreatic cancer	7.81e-08	1.4e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	6.84e-08	1.22e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	6.78e-08	1.21e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	6.77e-08	1.21e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	5.91e-08	1.06e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—pancreatic cancer	5.53e-08	9.89e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	4.17e-08	7.46e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.41e-08	6.09e-07	CbGpPWpGaD
